ROCKAWAY, N.J., May 01, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR) a commercial-stage bioelectronic medicine and wellness company, today announced that electroCore’s Chief Executive Officer, Dan Goldberger, will present at the Annual Aegis Virtual Conference being held May 2-4, 2023.
Aegis Capital Conference:
Date: Tuesday, May 2, 2023
Time: 4:00 PM ET
Event: Presentation here
About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health through its non-invasive vagus nerve stimulation (“nVNS”) technology platform. Our focus is the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance in the United States and select overseas markets.
For more information, visit www.electrocore.com.
Investors:
Rich Cockrell
CG Capital
404-736-3838
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$7.27 |
| Daily Change: | -0.12 -1.62 |
| Daily Volume: | 43,298 |
| Market Cap: | US$53.940M |
March 12, 2025 February 27, 2025 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
